Therefore, our findings provide a strong rationale for clinical trialstesting chemo-immunotherapy of ovarian cancer by combined PD-1 blockade using PD-1- orPD-L1-targeting mAb and GITR activation using GITR-specific mAb or GITRL fusion proteinand chemotherapeutic drugs. This evidence concerns the gene TNFRSF18 and ovarian cancer.